News
-
-
-
PRESS RELEASE
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population -
-
PRESS RELEASE
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités. Chiffre d’affaires en hausse, trésorerie solide et perspectives confirmées. Détails disponibles sur le site de la société -
PRESS RELEASE
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
PolyPeptide Group reports +24% revenue growth in H1 2025, revises full-year guidance towards upper range. EBITDA improved to EUR 4.4 million, major investments in capacity expansion projects -
PRESS RELEASE
TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV
TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV -
PRESS RELEASE
CoTec Holdings Corp. Announces Automatic Conversion of Kings Chapel Converitble Loan and Establishment of $6.6 Million in New Convertible Loan Facilities
CoTec Holdings Corp. announces repayment of convertible loan, new agreements with Kings Chapel and Epic Capital. Agreements for up to $5M and $1.6M respectively. Insights on ownership and share conversions -
-
